if the efficacy is not in line with secondary outcomes for FGSG....what's the rationale behind phase 3? are they expecting sub analysis to potentially trim patient type narrow and expect it to work?
- Forums
- ASX - By Stock
- DXB
- Ann: Quarterly Appendix 4C and Activities Report
Ann: Quarterly Appendix 4C and Activities Report, page-205
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add DXB (ASX) to my watchlist
(20min delay)
|
|||||
Last
39.0¢ |
Change
-0.015(3.70%) |
Mkt cap ! $214.7M |
Open | High | Low | Value | Volume |
41.5¢ | 41.5¢ | 37.0¢ | $2.682M | 6.983M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2585 | 38.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
39.5¢ | 52718 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2585 | 0.385 |
5 | 74771 | 0.380 |
5 | 222310 | 0.375 |
17 | 306799 | 0.370 |
5 | 140310 | 0.365 |
Price($) | Vol. | No. |
---|---|---|
0.395 | 52718 | 3 |
0.400 | 128996 | 5 |
0.405 | 5555 | 1 |
0.410 | 19423 | 1 |
0.415 | 120534 | 4 |
Last trade - 16.10pm 10/09/2024 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |